Research graph
References from Repeated voriconazole therapeutic drug monitoring in hospitalised patients: a real-world cohort study of out-of-range exposure and concentration response to dose adjustment. Local targets link to admitted publications; unresolved targets remain external evidence.
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
10.1093/jac/dkt508 · 2014 · External reference
Fitting linear mixed-effects models using lme4
10.18637/jss.v067.i01 · 2015 · External reference
Can we predict the influence of inflammation on voriconazole exposure? An overview
10.1093/jac/dkad293 · 2023 · External reference
Combined impact of inflammation and pharmacogenomic variants on voriconazole trough concentrations: a meta-analysis of individual data
10.3390/jcm10102089 · 2021 · External reference
brms: an R package for Bayesian multilevel models using Stan
10.18637/jss.v080.i01 · 2017 · External reference
Combined effect of CYP2C19 genetic polymorphisms and C-Reactive protein on voriconazole exposure and dosing in immunocompromised children
10.3389/fped.2022.846411 · 2022 · External reference
Voriconazole therapy and CYP2C19 genotype
2019 · External reference
Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity
10.1016/j.ijantimicag.2014.05.019 · 2014 · External reference
Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels
10.1128/aac.04838-14 · 2015 · External reference
Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications
10.1128/aac.00579-07 · 2007 · External reference
Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization
10.1111/bcp.15916 · 2023 · External reference
Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese
10.1111/1440-1681.13357 · 2020 · External reference
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
10.1056/nejmoa020191 · 2002 · External reference
Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction
10.1128/aac.01126-24 · 2024 · External reference
Unravelling voriconazole’s hepatic metabolism: a narrative review on factors impacting Voriconazole-N-Oxide exposure
10.1111/myc.70158 · 2026 · External reference
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
10.1093/jac/dkw045 · 2016 · External reference
CYP2C19-Guided voriconazole therapy: a precision medicine approach to mitigate adverse effects in Japanese patients
10.1111/cts.70317 · 2025 · External reference
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
10.1111/cts.13887 · 2024 · External reference
A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions
10.1007/s40262-019-00856-z · 2020 · External reference
Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis
10.3389/fphar.2024.1368274 · 2024 · External reference
Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis
10.3389/fphar.2024.1455721 · 2024 · External reference
The effect of rifapentine and rifampicin on serum voriconazole levels persist for 5 days and 7 days or more after discontinuation in tuberculosis patients with chronic pulmonary aspergillosis
10.2147/idr.s461785 · 2024 · External reference
Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults
10.1002/cpt.1012 · 2018 · External reference
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and voriconazole therapy
10.1002/cpt.583 · 2017 · External reference
Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America
10.1093/cid/ciw326 · 2016 · External reference
Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model
10.1016/j.ijantimicag.2023.106750 · 2023 · External reference
Inflammation is associated with voriconazole trough concentrations
10.1128/aac.03820-14 · 2014 · External reference
Voriconazole metabolism is influenced by severe inflammation: a prospective study
10.1093/jac/dkw349 · 2017 · External reference
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1590/s1135-57272008000300002 · 2008 · External reference
The development and validation of a predictive model for voriconazole-related liver injury in hospitalized patients in China
10.3390/jcm12134254 · 2023 · External reference
The effect of voriconazole on tacrolimus in kidney transplantation recipients: a real-world study
10.3390/pharmaceutics14122739 · 2022 · External reference
